TY - JOUR
T1 - Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery
AU - Zarei, Omid
AU - Benvenuti, Silvia
AU - Ustun-Alkan, Fulya
AU - Hamzeh-Mivehroud, Maryam
AU - Dastmalchi, Siavoush
PY - 2016
Y1 - 2016
N2 - Purpose: Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d’Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery. Methods: In this review, we will summarize the available agents against extracellular domain of RON with potential antitumor activities. Results: The presented antibodies and antibody drug conjugates against RON in this review showed wide spectrum of in vitro and in vivo antitumor activities promising the hope for them entering the clinical trials. Conclusion: Due to critical role of extracellular domain of RON in receptor activation, the development of therapeutic agents against this region could lead to fruitful outcome in cancer therapy.
AB - Purpose: Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d’Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery. Methods: In this review, we will summarize the available agents against extracellular domain of RON with potential antitumor activities. Results: The presented antibodies and antibody drug conjugates against RON in this review showed wide spectrum of in vitro and in vivo antitumor activities promising the hope for them entering the clinical trials. Conclusion: Due to critical role of extracellular domain of RON in receptor activation, the development of therapeutic agents against this region could lead to fruitful outcome in cancer therapy.
KW - Cancer
KW - Drug conjugate
KW - Monoclonal antibody
KW - Peptide
KW - Target therapy
KW - Tumor
KW - Tyrosine kinase receptor
UR - http://www.scopus.com/inward/record.url?scp=84981239702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981239702&partnerID=8YFLogxK
U2 - 10.1007/s00432-016-2214-4
DO - 10.1007/s00432-016-2214-4
M3 - Article
AN - SCOPUS:84981239702
SN - 0171-5216
SP - 1
EP - 18
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
ER -